119 related articles for article (PubMed ID: 16230412)
1. Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses.
Mezhir JJ; Advani SJ; Smith KD; Darga TE; Poon AP; Schmidt H; Posner MC; Roizman B; Weichselbaum RR
Cancer Res; 2005 Oct; 65(20):9479-84. PubMed ID: 16230412
[TBL] [Abstract][Full Text] [Related]
2. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
Fu X; Zhang X
Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
[TBL] [Abstract][Full Text] [Related]
3. A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus.
Fu X; Meng F; Tao L; Jin A; Zhang X
Gene Ther; 2003 Aug; 10(17):1458-64. PubMed ID: 12900760
[TBL] [Abstract][Full Text] [Related]
4. Herpes simplex virus 1 ICP27 is required for transcription of two viral late (gamma 2) genes in infected cells.
Jean S; LeVan KM; Song B; Levine M; Knipe DM
Virology; 2001 May; 283(2):273-84. PubMed ID: 11336552
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of the shutoff of protein synthesis by virion host shutoff and mutant gamma (1)34.5 genes of herpes simplex virus 1.
Poon AP; Roizman B
Virology; 1997 Mar; 229(1):98-105. PubMed ID: 9123882
[TBL] [Abstract][Full Text] [Related]
6. Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake.
Egami T; Ohuchida K; Mizumoto K; Onimaru M; Toma H; Nishio S; Nagai E; Matsumoto K; Nakamura T; Tanaka M
Clin Cancer Res; 2008 Mar; 14(6):1859-67. PubMed ID: 18347189
[TBL] [Abstract][Full Text] [Related]
7. c-Src-p38 mitogen-activated protein kinase signaling is required for Akt activation in response to ionizing radiation.
Kim MJ; Byun JY; Yun CH; Park IC; Lee KH; Lee SJ
Mol Cancer Res; 2008 Dec; 6(12):1872-80. PubMed ID: 19074832
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
9. Engineering cell lines for production of replication defective HSV-1 gene therapy vectors.
Grant KG; Krisky DM; Ataai MM; Glorioso JC
Biotechnol Bioeng; 2009 Mar; 102(4):1087-97. PubMed ID: 18828174
[TBL] [Abstract][Full Text] [Related]
10. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
Kuroda T; Rabkin SD; Martuza RL
Cancer Res; 2006 Oct; 66(20):10127-35. PubMed ID: 17047077
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus ICP27 is required for virus-induced stabilization of the ARE-containing IEX-1 mRNA encoded by the human IER3 gene.
Corcoran JA; Hsu WL; Smiley JR
J Virol; 2006 Oct; 80(19):9720-9. PubMed ID: 16973576
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the initiator and downstream promoter elements of herpes simplex virus 1 late genes.
Woerner AM; Weir JP
Virology; 1998 Sep; 249(2):219-30. PubMed ID: 9791014
[TBL] [Abstract][Full Text] [Related]
13. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD
BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613
[TBL] [Abstract][Full Text] [Related]
14. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways.
Park CM; Park MJ; Kwak HJ; Lee HC; Kim MS; Lee SH; Park IC; Rhee CH; Hong SI
Cancer Res; 2006 Sep; 66(17):8511-9. PubMed ID: 16951163
[TBL] [Abstract][Full Text] [Related]
15. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.
Liu TC; Wakimoto H; Martuza RL; Rabkin SD
Clin Cancer Res; 2007 Oct; 13(19):5897-902. PubMed ID: 17908985
[TBL] [Abstract][Full Text] [Related]
16. IL-2 withdrawal induces HTLV-1 expression through p38 activation in ATL cell lines.
Washiyama M; Nishigaki K; Ahmed N; Kinpara S; Ishii Y; Kanzawa N; Masuda T; Kannagi M
FEBS Lett; 2007 Nov; 581(27):5207-12. PubMed ID: 17950728
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.
Naito S; Obayashi S; Sumi T; Iwai S; Nakazawa M; Ikuta K; Yura Y
Cancer Gene Ther; 2006 Aug; 13(8):780-91. PubMed ID: 16645620
[TBL] [Abstract][Full Text] [Related]
18. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity.
Veerapong J; Bickenbach KA; Shao MY; Smith KD; Posner MC; Roizman B; Weichselbaum RR
Cancer Res; 2007 Sep; 67(17):8301-6. PubMed ID: 17804745
[TBL] [Abstract][Full Text] [Related]
19. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
Fu X; Tao L; Cai R; Prigge J; Zhang X
Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513
[TBL] [Abstract][Full Text] [Related]
20. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
